Beats Medical: An EIC Accelerator Story of Parkinson's Apps

People with Parkinson's disease often shuffle, take shorter steps or freeze on the spot. A steady external beat can help them walk more normally, a technique physiotherapists have used for decades. Ciara Clancy, a Dublin physiotherapist, put that beat into a smartphone app in 2012 and built Beats Medical around it. In the EIC SME Instrument Phase 2 cut-off of 3 April 2019 the company won an EU grant of €2,473,230.38 for Project SCALE, which was meant to turn its Parkinson's and dyspraxia apps into one platform that drug companies and health insurers could deploy for other brain disorders.

Seven years later Beats Medical is still trading. Its Parkinson's app was updated on 30 July 2026, it filed its 2025 accounts with the Irish Companies Registration Office in June 2026, and in November 2025 it listed the app with the US Food and Drug Administration. What is harder to find is the commercial result the grant was meant to produce: the company says it works with "Top 10 Global Pharma Companies", but it has not named one.

Where Beats Medical Stands Now

Beats Medical Limited is a live company. The Irish register, as shown by SoloCheck and Business Barometer, lists its status as normal, a financial statement for the year to 31 December 2025 filed on 4 June 2026, a change of registered office dated 22 May 2026 and a return of allotments, meaning newly issued shares, dated 15 May 2026. OpenCorporates records an earlier share allotment filed in July 2025. Who bought the new shares, and for how much, is not visible in the free register data. The company files as a small company, so its turnover and headcount are not public.

The company's sole shareholder is Beats Horizons Limited, a holding company incorporated on 5 November 2020 with six shareholders, the largest corporate one being CBA Ventures Unlimited Company, according to SoloCheck. The holding company also filed a share allotment in January 2026.

The Technology: A Beat, a Voice Meter and a Phone

The Parkinson's app combines three daily exercise modules. For walking, it plays a metronome beat tailored to the user's gait each day, which the company says targets shuffling, freezing, speed and stride length. For speech, it gives real-time visual feedback on loudness and intonation. For dexterity, it digitises occupational therapy hand exercises. The app adjusts the programme from assessments it runs on the phone's own sensors, with no extra hardware, according to the company's product page. In January 2019 Parkinson's UK added it to its app library, and it was registered in Europe as a class I medical device, Silicon Republic reported.

Rhythmic auditory cueing for Parkinson's is not new, and Beats Medical does not claim to have invented it. Its claim is delivery: the exercises a physiotherapist, speech therapist and occupational therapist would give in a clinic, tailored daily and done at home. Its second product, launched on 30 July 2018, applied the same engine to children with dyspraxia, a developmental coordination disorder, with game-like exercises. Ireland's largest private health insurer, Vhi, agreed to reimburse it, cutting the price for its members from €330 to €50 a year, according to the Vhi announcement.

Today the company sells the engine itself, under the name Colbolt. Its platform page describes four modules (gross motor, fine motor, speech and wellbeing) that can be deployed as a therapy app or as an assessment-only tool for clinical trials, white-labelled or co-branded for a partner. The home page now leads with clinical research for drug developers, claiming "x5 increase in data precision" over traditional methods; no study backing that figure is linked from the page.

What Project SCALE Promised, and What CORDIS Shows

The grant agreement was signed on 20 August 2019 and the project ran from 1 September 2019 to 31 August 2022, the dates CORDIS still lists, so it closed on schedule. Its objective was to "scale up our current core technology platform in order to further deploy the technology in greater disease areas", so that disease-specific products could be built quickly for the pharmaceutical and payer industries. Beats Medical was the only beneficiary; the Commission's list names no partner company for the project. In June 2019 it was one of eight Irish companies selected for EIC funding that round, according to Silicon Republic.

The final periodic report, covering September 2021 to August 2022, says the company built a "Beats Smart Platform", scaled its back end and front end, added machine learning to how therapies are tailored, and adapted its sales material to "our changing B2B market". It makes two commercial claims: that the technology was "being clinically piloted in a number of hospitals in the US and Europe", and that the company had "attained industry partnerships in the pharma and payer space". A CORDIS Results in Brief article from February 2023 adds that the apps were used in over 30 countries and reimbursed by public and private payers. Neither source names a hospital, a pharma partner or a new disease product.

1. Scale the core platformDeliveredThe Colbolt platform is marketed and the Parkinson's app is still updated, most recently on 30 July 2026, per the App Store.
2. Deploy in new disease areasPartlyAn MS mobility deployment reached a usability study with the Portuguese MS Society, published in August 2025. No commercial product beyond Parkinson's and dyspraxia is public.
3. Pharma and payer partnershipsNot verifiableClaimed in the CORDIS report and on the partner page; no pharma partner is named. The one named payer, Vhi, signed in 2018, before the grant.
4. Clinical pilots in US and European hospitalsNot verifiableReported in 2022 without hospital names or results.
5. Launch to marketDeliveredApps on sale in Europe; a US version listed with the FDA in November 2025.

The project delivered its engineering goal on time, and that should be credited: a small Irish firm rebuilt a consumer app into a configurable medical software platform and kept it on the market. The commercial goals are another matter. A grant funds development, not sales, but the company told the EU it had pharma partners and hospital pilots, and four years after the project ended none of them is public.

What Has Happened Since the Award

The clearest new step is in the United States. The FDA's establishment register lists Beats Medical, with Ciara Clancy as official correspondent, as the manufacturer of the "Beats Medical Application", listed on 28 November 2025 under product code HCC, a class II biofeedback device, according to openFDA. The listing carries no 510(k) clearance number. Under 21 CFR 882.5050, certain prescription biofeedback devices for relaxation training and muscle reeducation are exempt from premarket notification; the US App Store version describes itself as prescription-only and intended "to support the muscle re-education of ambulatory patients". The company's Parkinson's page says it is working to make the app available to US users "in 2026" and invites them to a waitlist; whether US patients can use it yet is not public.

Recognition came mostly to the founder. Clancy was one of the winners of the European Commission's EU Prize for Women Innovators 2022, announced on 7 December 2022; ThinkBusiness reported a €100,000 prize. The company also lists a 2022 European Patient Digital Health Award on its news page. Cathriona Hallahan, a former managing director of Microsoft Ireland, joined the board, according to the company's news page, and its team page lists her as chair.

Some numbers move the wrong way. In July 2018 Vhi said the Parkinson's app operated in "more than 44 countries"; since 2023 CORDIS and the company say "over 30". The figures are lower bounds and may be counted differently, but no source explains the change. The company's news page has had few new items since early 2024: an article on industry trends in February 2024 and the MS whitepaper in August 2025.

The Money

How Beats Medical is financed beyond the EU grant is largely not public. In October 2017 it was seeking a €3 million Series A as it moved from selling directly to patients at about €1 a day towards contracts with hospital groups, backed until then by angel investors including Sean Melly and Sam McCauley, Silicon Republic reported. No report of that round closing could be found. The data provider CB Insights puts total funding at $2.2 million over five rounds, which is less than the EU grant alone, so its figure cannot be complete. The share allotments filed in 2025 and 2026 show that new equity was issued, but not how much.

Why Europe Should Care

More than a billion people worldwide live with a neurological or brain disorder, the project summary on CORDIS notes, and the company's case rests on the waiting lists and costs that keep many of them from regular therapy. Software that brings structured therapy into patients' homes fits the EU's push for digital health, including the European Health Data Space Regulation (EU) 2025/327, which entered into force on 26 March 2025 and sets rules for using health data in care and research. Beats Medical's pitch to drug developers, objective symptom measures collected on patients' own phones, is the kind of secondary use of health data that regulation is meant to enable.

The company's path also shows where such firms look for scale. Its first reimbursement deal was with an Irish private insurer; its newest regulatory step is a US device listing, not a new approval or payer contract in another EU country.

The Verdict

Beats Medical has not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.